Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06555432
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-13
Brief Title:
A Study of LIVTENCITY Maribavir in Adults With Cytomegalovirus CMV Infection After Transplantation in South Korea
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Post-Marketing Surveillance Usage Results Study of LIVTENCITY Tablet Maribavir for the Approved Indications in South Korea
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cytomegalovirus CMV is a common virus that infects many people It can cause serious illness in people with weak immune systems especially in those undergoing transplants LIVTENCITY Maribavir is a medicine approved for treating CMV infection in adults after transplant in South Korea
The main aim of this study is to learn how safe and effective LIVTENCITY Maribavir is in treating adults with CMV infection after transplant in a routine clinical practice setting
During the study a participants data will be collected for about 5 months 20 weeks The study does not have fixed visits to the hospital but it is recommended to visit the study doctor approximately 6 times during study
The main aim of this study is to learn how safe and effective LIVTENCITY Maribavir is in treating adults with CMV infection after transplant in a routine clinical practice setting
During the study a participants data will be collected for about 5 months 20 weeks The study does not have fixed visits to the hospital but it is recommended to visit the study doctor approximately 6 times during study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None